N/A
N=10
An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia
Schizophrenia
Bottom Line
View on ClinicalTrials.gov: NCT00823199 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
May 2013
Primary outcome: Primary: Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia — 95; 75 scores on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Allopurinal (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Bronx Psychiatric Center
- Primary completion
- Aug 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia |
95; 75 | — |
| SECONDARY Simpson Angus Scale for Parkinsonism |
0.37; 1.75 | — |
Summary
This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects. No change in medication is required.
Eligibility Criteria
Inclusion Criteria
- Subjects with schizophrenia and poor response (no prospect of discharge because of symptoms)
Exclusion Criteria
- Over 65
- Renal or liver disease
- Diabetes
- Hypertension
- Taking thiazides or ACE inhibitors
Data sourced from ClinicalTrials.gov (NCT00823199). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.